NEWS | INDUSTRY
Major Pharmaceutical Acquisition Strengthens Non-Opioid Pain Treatment Portfolio .
The pharmaceutical market for non-opioid pain management is undergoing significant consolidation. Viatris announced plans to acquire Pacira BioSciences for $1.65 billion, adding 2 established treatments to its portfolio: Exparel, a long-acting postoperative analgesic, and Zilretta, an extended-release corticosteroid injection for knee osteoarthritis. The acquisition highlights growing commercial interest in reducing opioid exposure following surgery and expanding nonsurgical pain-management options. The transaction is expected to close by the end of 2026.
Read the full News article from Reuters
Read ArticleDISCLAIMER
This content found on this page is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you require medical treatment, always seek the advice of your physician or go to your nearest emergency department. The opinions, beliefs, and viewpoints expressed by the individuals on the content found on this page do not reflect the opinions, beliefs, and viewpoints of OrthoEvidence.